Literature DB >> 12109782

Vimentin expression does not assist in predicting survival in ductal carcinoma of the breast.

M K Heatley1, P Ewings, W Odling Smee, P Maxwell, P G Toner.   

Abstract

AIMS: To establish the value of vimentin expression in predicting survival in patients with breast cancer.
METHODS: Five-year follow-up data were obtained for 68 patients with ductal carcinoma (NOS) of the breast in whom vimentin expression had been studied in fresh frozen and formalin-fixed, paraffin-embedded tissue. The predictive value on survival of tumour size, growth fraction (as assessed using the Ki67 monoclonal antibody), oestrogen receptor status and Bloom and Richardson grade of the primary tumour, and the presence or absence of lymph node metastases in axillary samples, were also studied.
RESULTS: Twenty-two patients died of their disease within 5 years of diagnosis. Vimentin expression either on frozen or paraffin sections did not provide a statistically significant prediction of survival. On univariate analysis tumour grade, size and the presence of lymph node metastases provided prognostic information. Only lymph node status was of independent prognostic importance on multivariate analysis.
CONCLUSIONS: Whilst these results confirm the value of established prognostic factors, they do not support the use of vimentin expression in either fresh or fixed tissue for the prediction of survival in ductal carcinoma (NOS) of the breast.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12109782     DOI: 10.1080/00313020220131273

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  7 in total

1.  Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma.

Authors:  Seema Sethi; Fazlul H Sarkar; Quratulain Ahmed; Sudeshna Bandyopadhyay; Zeina A Nahleh; Assaad Semaan; Wael Sakr; Adnan Munkarah; Rouba Ali-Fehmi
Journal:  Transl Oncol       Date:  2011-08-01       Impact factor: 4.243

2.  Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas.

Authors:  Socorro María Rodríguez-Pinilla; David Sarrió; Emiliano Honrado; Gema Moreno-Bueno; David Hardisson; Francisco Calero; Javier Benítez; José Palacios
Journal:  J Clin Pathol       Date:  2006-11-14       Impact factor: 3.411

3.  Vimentin as a poor prognostic factor for triple-negative breast cancer.

Authors:  Nami Yamashita; Eriko Tokunaga; Hiroyuki Kitao; Yuichi Hisamatsu; Kenji Taketani; Sayuri Akiyoshi; Satoko Okada; Shinichi Aishima; Masaru Morita; Yoshihiko Maehara
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-26       Impact factor: 4.553

4.  Does vimentin help to delineate the so-called 'basal type breast cancer'?

Authors:  Renata U Kusinska; Radzislaw Kordek; Elzbieta Pluciennik; Andrzej K Bednarek; Janusz H Piekarski; Piotr Potemski
Journal:  J Exp Clin Cancer Res       Date:  2009-08-20

5.  Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.

Authors:  E de Azambuja; F Cardoso; G de Castro; M Colozza; M S Mano; V Durbecq; C Sotiriou; D Larsimont; M J Piccart-Gebhart; M Paesmans
Journal:  Br J Cancer       Date:  2007-04-24       Impact factor: 7.640

6.  Vimentin and Notch as biomarkers for breast cancer progression.

Authors:  Gloria M Calaf; Adayabalam S Balajee; Maria T Montalvo-Villagra; Mariana Leon; Navarrete M Daniela; Raúl González Alvarez; Debasish Roy; Gopeshwar Narayan; Jorge Abarca-Quinones
Journal:  Oncol Lett       Date:  2014-01-03       Impact factor: 2.967

7.  Epithelial-Mesenchymal Transition Markers in Breast Cancer and Pathological Responseafter Neoadjuvant Chemotherapy.

Authors:  Shaimaa Elzamly; Nabeel Badri; Osvaldo Padilla; Alok Kumar Dwivedi; Luis A Alvarado; Matthew Hamilton; Nabih Diab; Crosby Rock; Ahmed Elfar; Marwa Teleb; Luis Sanchez; Zeina Nahleh
Journal:  Breast Cancer (Auckl)       Date:  2018-08-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.